For cancer patients navigating the uncertainty of early-phase clinical trials (EPCTs), coping style may be just as important as treatment itself. A prospective study published in the Journal of the National Comprehensive Cancer Network enrolled 188 adults with solid tumors at Massachusetts General Hospital and found that how patients mentally handle their situation has measurable effects on their well-being.

Patients who leaned into approach-oriented strategies — acceptance, emotional support, and positive reframing — reported higher quality of life and lower rates of depression and anxiety. On the flip side, avoidance strategies like self-blame, denial, and behavioral disengagement were associated with greater symptom burden and worse mental health outcomes. Notably, denial was linked to fewer hospitalizations, while emotional support and positive reframing were paradoxically associated with shorter overall survival — a finding the researchers say warrants further investigation.

Key Takeaways:

• Acceptance, emotional support, and positive reframing were tied to better quality of life and lower depressive and anxiety symptoms
• Self-blame and behavioral disengagement correlated with higher symptom burden
• Denial was associated with fewer hospitalizations but did not improve survival
• Women used emotional support, positive reframing, and religion more than men
• Older patients were less likely to use self-blame as a coping strategy

Why it matters: These findings highlight a largely overlooked dimension of cancer trial care — the psychological toolkit patients bring with them. Integrating coping assessments and targeted supportive care interventions into EPCT programs could meaningfully improve patient outcomes beyond the trial drug itself.